Methods for treatment of heart failure

Abstract

Disclosed are methods, compositions and kits for treating or preventing heart failure. Methods of the invention treating heart failure in a mammal comprising administering to the mammal an effective amount of a thienopyrimidine compound.

1 - 20 . (canceled) 
     
     
         21 . A method of treating heart failure in a mammal, the method comprising administering an effective amount of a compound having the structure, 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof; 
         wherein the compound is co-administered with an Angiotensin-Converting Enzyme (ACE) inhibitor. 
       
     
     
         22 . The method of  claim 21  wherein the Angiotensin-Converting Enzyme (ACE) Inhibitor is selected from the group consisting of Captopril, Enalapril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, and Trandolapril. 
     
     
         22 . The method of  claim 21  wherein the mammal is suffering from or has suffered from heart failure. 
     
     
         23 . The method of  claim 21  wherein a mammal that is suffering from or has suffered from heart failure is selected for heart failure treatment and the compound is administered to the selected mammal. 
     
     
         24 . The method of  claim 21  wherein the mammal is identified as exhibiting congestive heart failure disorder having low cardiac output and/or low stroke volume. 
     
     
         25 . The method of  claim 21  wherein the mammal has suffered from congestive heart failure. 
     
     
         26 . The method of  claim 21  wherein the mammal has suffered from cardiogenic shock. 
     
     
         27 . The method of  claim 21  wherein the mammal is a human. 
     
     
         28 . The method of  claim 21  wherein the effective amount is from 0.01 to 10 mg/kg per day. 
     
     
         29 . The method of  claim 21  wherein the compound is comprised in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier. 
     
     
         30 . The method of  claim 29  wherein the pharmaceutical composition is formulated for administering purposes in a capsule, a tablet, a gel, a powder, liquid, suspension or emulsion.